USC researchers link unusual DNA structure to cancer

March 03, 2004

Los Angeles, March 4, 2004 - University of Southern California researchers have discovered an unusual DNA structure in the chromosomes of lymphocytes that appears to create a so-called "fragile site" on the chromosome and to predispose cells carrying it to develop a common form of non-Hodgkin's lymphoma.

"This is the first disease ever to be associated with a deviation from the Watson-Crick helix," says Michael R. Lieber, M.D., Ph.D., Keck School of Medicine professor of pathology and biochemistry, the Rita and Edward Polusky Chair in Basic Cancer Research and the study's principal investigator.

The paper will be published in the March 4 issue of the journal Nature.

Lieber and colleagues had previously used similar techniques to uncover the first new, stable structure in DNA, which was associated with an antibody-production process called class switching. This structure, however, looks different from the previous structure found, and is further distinguished by being associated with cancer.

The fragile site in question is located on the Bcl-2 gene on chromosome 18. Bcl-2 is a gene that normally plays a role in blocking apoptosis, or cellular suicide. When it is overexpressed, however, it results in a form of B-cell lymphoma (hence the name Bcl) called follicular lymphoma.

The fragile site found on the Bcl-2 gene is the most common fragile site in all of cancer, according to Lieber. "That one break site, which is only about 120 base pairs long, is responsible for 4 percent of all cancers," he says.

In order to cause follicular lymphoma, the fragile site on chromosome 18 must experience a break, and then trade bits of DNA with chromosome 14. This is a well-known phenomenon in the world of oncology research and treatment, and is called the 14;18 translocation.

"Of all the chromosomal fragile sites in cancer, this is the first one where we've actually understood why it's fragile," Lieber says. "And it's because of this molecular quirk in the Watson-Crick helix."

Follicular lymphoma is the second-most common form of non-Hodgkin's lymphoma, with somewhere between 13,000 and 22,000 cases being diagnosed each year, generally in older individuals. The five-year survival rate is around 75 percent.

Lieber credits this and related discoveries in his lab to a technique developed in conjunction with the USC/Norris laboratory of his wife, Chih-Lin Hsieh, Ph.D., associate professor of biochemistry and molecular biology and urology at the Keck School of Medicine. "It's called the bisulfide method," Lieber explains. "It's based on the fact that when you treat DNA with bisulfide, the cytosine bases of the DNA undergo a transformation. But they only undergo that transformation if they're in a single-stranded region. If they are in the normal double-stranded configuration, they do not undergo the transformation. So this has allowed us to pinpoint areas of DNA that are not arranged in a double helix and to explore them."

There's plenty of work left to be done before the fragile site is fully understood, notes Sathees Chukkurumbal Raghavan, Ph.D., a research associate in the Lieber laboratory and the paper's first author. "While we know it deviates from the standard helix, we don't know what the base pairing is at the fragile site," he explains.

Lieber is equally unsure as to whether this finding will have a therapeutic application down the road. "It's important to know how and why cancer begins," he says. "And this is an important step to understanding that--to understanding why the break is happening and why the chromosomes are swapping arms.

"We already knew that this translocation throttles the Bcl-2 up, making the cell invincible--and making it a good cancer cell," Lieber adds. "But nobody knew why it was happening. Now we are beginning to understand."
-end-
A News and Views article accompanies the paper.

Lieber's work is funded by the National Institutes of Health.

Sathees C. Raghavan, Patrick C. Swanson, Xiantuo Wu, Chih-Lin Hsieh, Michael R. Lieber, "A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex." Nature, March 4, 2004.

University of Southern California

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.